

1 **Appendix Table 1. Median anti-SARS-CoV-2 serum antibody titers and ratios post-vaccination and**  
 2 **post-infection by isotype among participants (N=11) in a nursing home cohort—Georgia, October**  
 3 **2020–April 2021\***

Time period (days)	Post-infection		Post-vaccination		Ratio post-vaccination to post-infection
	No. specimens tested	Median titer (IQR) <sup>†</sup>	No. specimens tested	Median titer (IQR) <sup>‡§</sup>	
<i>Pan-Ig</i>					
0–14	5	286 (257–1803)	9	5137 (3584–73070)	18.0
15–30	7	1,441 (1289–3682)	8	299,721 (240573–345136)	208.0
31–60	9	4,769 (2832–7582)	9	64,344 (55171–127753)	13.5
61–90	3	4,763 (2832–6153)	4	53,664 (38454–71967)	11.3
<i>IgG</i>					
0–14	5	395 (298–3340)	9	11,758 (5797–25900)	29.8
15–30	7	3,563 (2662–8028)	8	206,062 (95411–1258378)	57.8
31–60	9	7,472 (4952–15971)	9	380,248 (318681–8705015)	50.9
61–90	3	6,973 (6495–7217)	4	130,964 (73799–185779)	18.8
<i>IgA</i>					
0–14	3	155 (134–223)	3	399 (288–645)	2.6
15–30	7	318 (277–697)	8	2,777 (1178–4462)	8.7
31–60	7	198 (154–1255)	9	1,956 (754–4242)	9.9
61–90	3	399 (379–445)	4	656 (272–1742)	1.6

4 Abbreviations: IQR = interquartile range


5 \*The post-infection period was defined as the time from SARS-CoV-2 diagnosis (by BinaxNOW™ COVID-  
 6 19 Ag Cards and/or real-time reverse transcription polymerase chain reaction) to receipt of first Pfizer-  
 7 BioNTech COVID-19 Vaccine dose. The post-vaccination period was defined as the time after receipt of  
 8 first vaccine dose to the end of the evaluation period. Individuals with serum antibody titers below the  
 9 seroconversion threshold (defined as a signal threshold >1 at the 1:100 dilution for any isotype) were  
 10 not included in median and ratio calculations.

11 † Median post-infection titers peaked during 15–30 days for IgM, 31–60 days for Pan-Ig and IgG, and 61–  
 12 90 days for IgA.

13 † Participant C was not included in the post-vaccination analyses due to vaccination refusal. This  
14 participant's titers ranged from 2437–16977 for Pan-Ig, 4919–7045 for IgG, and 267–710 for IgA during  
15 the 90–150 days post-infection; their IgM titers were below the limit of detection during this time  
16 period.

17 § Median post-vaccination titers peaked during 15–30 days for Pan-Ig and IgA, and 31–60 days for IgG.  
18 Post-vaccination median IgM titers were not calculated because most post-vaccination titers were  
19 below the limit of detection.


20 **Appendix Figure 1. Detection of SARS-CoV-2 by BinaxNOW™ rapid antigen test, real-time reverse**  
 21 **transcription polymerase chain reaction, and viral culture by Pan-Ig serum antibody titers and days**  
 22 **post-diagnosis of participants (N=11) in a nursing home cohort—Georgia, October 2020–April 2021**



24 Abbreviations: BinaxNOW = BinaxNOW™ COVID-19 Ag Card; RT-PCR = real-time reverse transcription  
 25 polymerase chain reaction; Cx = viral culture





26 Blood samples were obtained at several timepoints between 1–150 days post-diagnosis (time period  
 27 after each participant’s first positive SARS-CoV-2 test result). Due to challenges phlebotomizing some  
 28 participants, serum titers were not generated for each participant for each visit. Participants with serum  
 29 antibody titers below the seroconversion threshold (defined as a signal threshold >1 at the 1:100  
 30 dilution for any isotype) were assigned a value of 25 for graphical representation only. The y-axis is  
 31 plotted in logarithmic scale.





32 **Appendix Figure 2. Anti-SARS-CoV-2 serum antibody titers by isotype and days post-diagnosis among**  
 33 **participants (N=11) in a nursing home cohort—Georgia, October 2020–April 2021**







35 Colored lines represent individual participants. Blood samples were obtained at several timepoints  
 36 between 1–150 days post-diagnosis (time period after each participant’s first positive SARS-CoV-2 test  
 37 result). Due to challenges phlebotomizing some patients, serum titers were not generated for each  
 38 participant for each visit. Pfizer-BioNTech COVID-19 vaccines were administered at the facility between  
 39 71–105 days post-diagnosis; participant C declined vaccination. Participants with serum antibody titers  
 40 below the seroconversion threshold (defined as a signal threshold >1 at the 1:100 dilution for any  
 41 isotype) were assigned a value of 25 for graphical representation only. The y-axis is plotted in  
 42 logarithmic scale.

43 **Appendix Figure 3. Anti-SARS-CoV-2 serum antibody titers by isotype and detection of SARS-CoV-2 by**  
44 **BinaxNOW™ rapid antigen test, real-time reverse transcription polymerase chain reaction, and viral**  
45 **culture post-diagnosis, by participant (N=11) in a nursing home cohort—Georgia, October 2020–April**  
46 **2021**

**Titer****Ct value****Titer****Ct value****Titer****Ct value****Days post-diagnosis**



**Titer****Days post-diagnosis****Ct value****Titer****Days post-diagnosis****Ct value****Titer****Days post-diagnosis****Ct value****Titer****Days post-diagnosis****Ct value**

48 Abbreviations: BinaxNOW = BinaxNOW™ COVID-19 Ag Card; RT-PCR = real-time reverse transcription  
49 polymerase chain reaction; Cx = viral culture

50 Blood samples were obtained at several timepoints between 1–150 days post-diagnosis (time period  
51 after each participant’s first positive SARS-CoV-2 test result). Due to challenges phlebotomizing some  
52 patients, serum titers were not generated for each participant for each visit. Pfizer-BioNTech COVID-19  
53 vaccines were administered at the facility between 71–105 days post-diagnosis; participant C declined  
54 vaccination. Participants with serum antibody titers below the seroconversion threshold (defined as a  
55 signal threshold >1 at the 1:100 dilution for any isotype) were assigned a value of 25 for graphical  
56 representation. The y-axis is plotted in logarithmic scale.